New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
10:35 EDTNBR, IPG, SNV, NI, CYTR, HZNPHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
News For HZNP;NI;IPG;CYTR;SNV;NBR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:58 EDTNBROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:22 EDTNBR, NBRNabors Industries downgraded to Underperform from Outperform at CLSA
CLSA downgraded Nabors Industries to Underperform from Outperform despite raising its price target to $16 from $13. CLSA's analyst believes the advancement of unconventional drilling has been one of the most disruptive technologies in the sectors' history and will derail cycle normalization near-term. The firm believes the industry will need half as many rigs to keep production flat until attrition right-sizes the industry.
May 22, 2015
09:58 EDTHZNPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allison Transmission (ALSN) initiated with a Buy at Stifel... Avago (AVGO) initiated with a Buy at Mizuho... Blackstone (BX) initiated with a Positive at Susquehanna... Cellectis (CLLS) initiated with an Outperform at Oppenheimer... Cypress Semiconductor (CY) initiated with a Buy at Mizuho... Esperion (ESPR) initiated with a Sell at Chardan... H&R Block (HRB) initiated with an Overweight at Piper Jaffray... Horizon Pharma (HZNP) initiated with an Outperform at Leerink... M/A-COM (MTSI) initiated with a Buy at Goldman... Meritor (MTOR) initiated with a Hold at Stifel... Micron (MU) initiated with a Buy at Mizuho... Monster Worldwide (MWW) initiated with a Neutral at Piper Jaffray... NXP Semiconductors (NXPI) initiated with a Buy at Mizuho... National Storage (NSA) initiated with a Sector Weight at KeyBanc... ON Semiconductor (ON) initiated with a Buy at Mizuho... Qorvo (QRVO) initiated with a Buy at Goldman... SanDisk (SNDK) initiated with a Neutral at Mizuho... Sharps Compliance (SMED) initiated with a Buy at Stifel... Skyworks (SWKS) initiated with a Buy at Mizuho... StemCells (STEM) initiated with a Buy at Cantor... Synaptics (SYNA) initiated with a Buy at Mizuho... Synergy Pharmaceuticals (SGYP) initiated with a Buy at Canaccord... Texas Instruments (TXN) initiated with a Neutral at Mizuho... TriNet (TNET) initiated with a Neutral at Piper Jaffray... Vascular Biogenics (VBLT) initiated with a Buy at Roth Capital... Verifone (PAY) initiated with an Outperform at Imperial Capital... uniQure (QURE) initiated with an Outperform at Oppenheimer.
07:06 EDTHZNPHorizon Pharma initiated with an Outperform at Leerink
Subscribe for More Information
May 21, 2015
12:40 EDTHZNPHayman's Bass requests review of POZEN patents
Subscribe for More Information
09:04 EDTCYTRCytRx's aldoxorubicin shows positive Phase 2 results for brain cancer
CytRx announced positive updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme, a deadly form of brain cancer. The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide. 18 study subjects have received between 1 and 14 cycles of aldoxorubicin, with 4 subjects continuing to receive aldoxorubicin treatment. 2 subjects diagnosed with tumor progression following aldoxorubicin treatment demonstrated no microscopic evidence of tumor tissue after resection. Fourteen of 18 subjects discontinued aldoxorubicin treatment, although there is a significant possibility that some of the patients experienced pseudo-progression. Following discontinuation of aldoxorubicin treatment, 10 of 14 subjects received treatment with bevacizumab for 1 to 14 cycles. Deaths have occurred in only 4 of 18 subjects to date, with survival duration so far of up to 10 plus months. Aldoxorubicin was well tolerated at both dose levels with all adverse events consistent with known doxorubicin toxicities, but not cardiotoxity.
07:25 EDTNBRUBS to hold a conference
Subscribe for More Information
May 19, 2015
07:26 EDTHZNPHorizon Pharma meeting takeaways support investment thesis, says UBS
Subscribe for More Information
May 18, 2015
15:29 EDTNIOptions with increasing volume
Options with increasing volume: ACHN PAGP CBG NI NGLS LEA OKS GTI WETF URBN
07:14 EDTNIAmerican Gas Association to hold a forum
Subscribe for More Information
May 15, 2015
10:01 EDTHZNPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma initiated with a Buy at Jefferies
Target $37.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use